Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111655 | 0.91 | ALDH1A1 (0.42) | PLA2G2CSMN1; SMN2RECQLKMT2APOLB | |
| SCHEMBL112318 | 0.88 | PLA2G2C (0.47) | PLA2G2CSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL123106 | 0.88 | PLA2G2C (0.47) | PLA2G2CSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL112227 | 0.88 | PLA2G2C (0.47) | PLA2G2CSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL27864511 | 0.88 | PLA2G2C (0.47) | PLA2G2CSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL113586 | 0.88 | PLA2G2C (0.47) | PLA2G2CSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL120629 | 0.88 | PLA2G2C (0.47) | PLA2G2CSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL110196 | 0.87 | L3MBTL1 (0.46) | L3MBTL1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL109560 | 0.83 | THRB (0.37) | L3MBTL1SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL5807775 | 0.81 | PLA2G2C (0.37) | PLA2G2CL3MBTL1SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8513243-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8362013-B2 | Salt of ABT-263 and solid-state forms thereof | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362014-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2477972-A1 | ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR USE IN TREATING BCL-2 PROTEIN RELATED DISEASES | Abbott Laboratories (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2442789-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | Abbott Laboratories (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2424849-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011034934-A1 | ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR USE IN TREATING BCL-2 PROTEIN RELATED DISEASES | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2010147899-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | ABBVIE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES | 2010-11-25 | — | — | US | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | disclosed |
| WO-2010127190-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | BCL2L10, TMBIM6, BCOR | PLA2G2C 1555/4885L3MBTL1 479/4885SMN1; SMN2 99/4885 |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCL2L2 | PLA2G2C 2060/4885L3MBTL1 278/4885SMN1; SMN2 775/4885 |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | BCL3, BCL2, BCL2L13 | PLA2G2C 1899/4885L3MBTL1 134/4885SMN1; SMN2 353/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | PLA2G2C 631/4885L3MBTL1 375/4885SMN1; SMN2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.